Media, investors, advocacy organizations and others, please contact us here.

Publications FSGS

Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study

View
Publications

Physiologically-based Pharmacokinetic Model of Sparsentan to Evaluate Drug-drug Interaction Potential

View
Publications IgAN

Sparsentan Is Superior to Losartan in the gddY Mouse Model 1 of IgA Nephropathy

View
Publications IgAN

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

View
Medical Information IgAN

FILSPARI (sparsentan) – 2-Year Results from the Phase 3 PROTECT Study Published in The Lancet

Medical Information FSGS

FILSPARI (sparsentan) – 2-Year Results from the Phase 3 DUPLEX Study Published in the NEJM

Abstracts IgAN

Sparsentan receptor occupancy modeling, clinical actions, and safety

View
Abstracts IgAN

Sparsentan as First-Line Treatment of Incident Patients with IgA Nephropathy: Preliminary Findings from the SPARTAN Trial

View
Posters IgAN

Sparsentan Reduces Proteinuria in Patients With Immunoglobulin A Nephropathy (IgAN): Interim Results of the Protect Study

Posters IgAN

Sparsentan Reduces Proteinuria in Patients With Immunoglobulin A Nephropathy (IgAN): Interim Results of the PROTECT Study

Posters IgAN

Immunoglobulin A Nephropathy (IgAN) Patient Baseline Characteristics in Asian Versus Non-Asian Regions in the Sparsentan PROTECT Study

Posters

Long-Term Efficacy and Safety of Sparsentan in Young Patients With FSGS: 240-Week Analysis of the DUET Open-Label Extension (OLE)

Abstracts IgAN

Sparsetan Reduces Proteinuria in Patients with Immunoglobulin A Nephropathy (IgAN): Interim Results of the PROTECT Study

View